Compare Norfolk Southern Corporation (NSC) vs Royalty Pharma plc Class A Ordinary Shares (RPRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Norfolk Southern Corporation vs Royalty Pharma plc Class A Ordinary Shares — how do they compare? Norfolk Southern Corporation trades at $316.96 (market cap $71.20B), while Royalty Pharma plc Class A Ordinary Shares trades at $56.74 (market cap $25.27B). The key difference: Norfolk Southern Corporation is far larger — about 2.8× Royalty Pharma plc Class A Ordinary Shares's market cap, and Norfolk Southern Corporation pays the higher dividend (1.7%). Which is the better fit depends on your goals — on Pluang, investors hold Norfolk Southern Corporation for 33 Days and Royalty Pharma plc Class A Ordinary Shares for 0 Days on average.
| NSC | RPRX | |
|---|---|---|
Market Cap | $71.20B | $25.27B |
Volume | 555,248 | 3,671,183 |
Sector | Industrials | Health |
52-Week High | $352.98 | $63.96 |
52-Week Low | $278.19 | $35.44 |
Typical Hold Time | 33 Days | 0 Days |
Enterprise Value | $86.75B | $32.50B |
Dividend Yield | 1.7% | 1.66% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Norfolk Southern (NSC) trades at $313.20, down 0.98% on the day, with a bearish technical outlook despite strong fundamentals. The company has consistently beaten earnings expectations in recent quarters, with Q2 2026 EPS of $3.52 exceeding the $3.32 forecast. Key developments include the proposed merger with Union Pacific, which is progressing through regulatory review and expected to close by late 2027. Financial metrics show solid profitability with 21.02% net income margin and 16.97% ROE, though cash flow trends indicate negative net cash flow in both 2025 and 2026.
The investment case balances strong operational performance against merger execution risks and technical weakness. With 44% analyst buy ratings and a $361.86 consensus price target suggesting 15% upside, the stock offers value if merger benefits materialize. However, regulatory hurdles, fuel cost pressures, and bearish technical signals warrant caution for near-term investors.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Norfolk Southern Corporation
Norfolk Southern Corporation is a major North American railroad company operating one of the largest freight rail networks in the eastern United States. The company transports a diverse range of commodities, including coal, intermodal containers, and various industrial products. NSC is a critical link in the nation's supply chain, providing efficient, long-haul transportation services to and from ports and industrial centers.
Read more on NSC →About Royalty Pharma plc Class A Ordinary Shares
Royalty Pharma acquires interests in royalties from biopharmaceutical products. Its model gives it exposure to medicines developed and sold by other life sciences companies.
Read more on RPRX →
